Viz.ai Wins Prestigious Prix Galien USA Award for Best Digital Health Solution

Recognition highlights the transformative patient impact of AI-powered care coordination

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received the 2024 Prix Galien USA Award for Best Digital Health Solution for its Viz HCM™ (Hypertrophic Cardiomyopathy) module. Often referred to as the "Nobel Prize of life sciences," the Prix Galien Award is one of the highest accolades in the field, recognizing outstanding innovations that improve human health.

"We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “For many with HCM, the path to diagnosis and treatment is often lengthy and challenging. Viz HCM is accelerating the patient journey for this serious yet significantly underdiagnosed disease by getting patients diagnosed faster and the appropriate follow-up care they need. I would like to express my gratitude to everyone on the Viz.ai team and HCM thought leaders, who contributed to its development.”

Viz HCM is the first and only solution with clearance by the U.S. Food and Drug Administration (FDA) that uses artificial intelligence to analyze all 12-lead electrocardiograms (ECGs) from across a health system to identify suspected HCM cases, notify cardiology care teams and ensure that patients get the right diagnosis and follow-up. Bristol Myers Squibb (BMS) provided funding to Viz.ai to develop the Viz HCM technology. The Viz HCM module was granted De Novo approval by the FDA in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software.

The Prix Galien Awards are organized by the Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences. Viz HCM was selected from a highly competitive group of 21 nominees in the 'Best Digital Health Solution' category. The Prix Galien USA Awards are determined by a distinguished panel of 13 leaders in life sciences, whose expertise and insights make this recognition particularly meaningful.

In particular, the Prix Galien Digital Health Advisory Board 2024 included leaders across the technology and life sciences industry with executives from Google, Microsoft, and Amazon. The Prix Galien Committee Chair was Kenneth C. Frazier, the former Chairman and CEO of Merck, and other panelists on the Prix Galien Committee for Digital Health included leaders at Sanofi, AstraZeneca, Johnson & Johnson, Pfizer, and UCB.

As a Prix Galien Award recipient, Viz.ai was honored with the Galien Medal and a certificate of recognition from the Galien Foundation, joining an esteemed community of innovators committed to advancing healthcare and improving patient outcomes.

For more information on Viz.ai, visit Viz.ai/life-sciences.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One^TM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.